All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
Results from the ongoing study continue to demonstrate prolonged clinical benefits, alongside favorable tolerability, and translational data linking the observed clinical benefits with DPX-Survivac’s mechanism of action.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
Breakthrough Therapy designation was based on an ongoing clinical trial of zanidatamab in patients with locally advanced (unresectable) and/or metastatic HER2-expressing tumors including BTC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The KOLs will provide an update on the ongoing Phase 2 trial with IMV’s novel T cell therapy in patients with advanced ovarian cancer, along with insights about the patients' experience.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Company’s T cell therapy demonstrates an 86% objective response rate in combination with Merck’s Keytruda® (pembrolizumab) in patients with Program Death Ligand 1 (PD-L1) positive relapsed / refractory diffuse large B-cell lymphoma (r/r DLBCL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Abstract titled "Clinical effectiveness of combination immunotherapy with DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The SPiReL Study" will presented the The American Society of Hematology Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DPX-Survivac,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: DPX-Survivac
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Poster titled "Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab" will be delivered at the Society for Immunotherapy of Cancer Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lasofoxifene,Abemaciclib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Sermonix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 30, 2020
Details:
With the recent Health Canada agreement to proceed, the open-label, randomized Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1, NCT03781063) study will now include Exactis Network sites in Quebec, Ontario, Nova Scotia and New Brunswick.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): QBECO SSI
Therapeutic Area: Oncology Product Name: QBECO SSI
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
The study is designed to assess the effect of QBECO SSI treatment on immune function in the tumor and systemically in patients newly diagnosed with colon cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
The primary purpose of Study II is to discover if the TLD-1433 combined with TLC-3200 (“Study Device”) are effective in the destruction of Bacillus Calmette-Guérin Unresponsive Non-Muscle Invasive Bladder Cancer.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
